Enzymotec Ltd.'s carDiabeat line is designed specially to fight the major risks for cardiovascular disorders of diabetes patients. The line simultaneously tackles the three major causes for cardiovascular diseases: prevention and control of oxidative stress, reduction of total cholesterol and triglyceride levels, and inhibition of the atherosclerotic plaque formation cascade. carDiabeat is based on a clinically proven and proprietary combination of enzymatically derived natural lipids, including DHA and EPA, in a unique delivery system that enhances their efficacy and bioavailability. Enzymotec, Sharon Maraton, +972-4-6545112, sharon@enzymotec.com